Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
June 15, 2023 08:00 ET
|
Satsuma Pharmaceuticals
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration...
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
May 18, 2023 16:01 ET
|
Satsuma Pharmaceuticals
January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended...
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
April 21, 2023 08:00 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
SNBL to Acquire Satsuma Pharmaceuticals
April 16, 2023 19:41 ET
|
Satsuma Pharmaceuticals
Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma...
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 28, 2023 16:05 ET
|
Satsuma Pharmaceuticals
- Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects - - Submitted...
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
February 02, 2023 08:00 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
December 20, 2022 09:21 ET
|
Satsuma Pharmaceuticals
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on...
Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022 13:59 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine
November 14, 2022 07:00 ET
|
Satsuma Pharmaceuticals
STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom STS101 showed superiority (p<0.001)...
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022 16:05 ET
|
Satsuma Pharmaceuticals
- On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 - - $64.4 million in cash, cash equivalents and marketable...